Shots:

• The companies entered into an exclusive research agreement for the discovery of novel small molecules targeting α-synuclein for the potential treatment of synucleinopathies including PD and dementia with Lewy bodies
• The collaboration will use Wren’s network kinetics drug discovery platform along with Eisai’s experience in drug discovery for neurodegenerative disorders- to accelerate the development of clinical candidates
• The agreement focuses on developing a disease-modifying treatment for synucleinopathies based on network kinetics of α-synuclein misfolding and aggregation

 ­ Ref: Businesswire | Image: Betahaus I Berlin